

CURRICULUM VITAE
Charles L. Daley, M.D., FCCP

I. Educational and Training History

Undergraduate:

1975-1979 University of Mississippi
B.A. in Zoology and Chemistry, *Summa Cum Laude*

Medical:

1979-1983 University of Mississippi Medical Center
Degree: M.D., *Summa Cum Laude*, Valedictorian

Internship/Residency:

1983-1986 Categorical Medical Internship/Residency
University of California, San Francisco
Lloyd H. Smith, M.D., Chairman through 1985
Richard K. Root, M.D., Chairman, 1985 to 1989

1986-1987 Chief Medical Resident
San Francisco General Hospital
Merle A. Sande, M.D., Chief of Medical Service

Fellowship:

1988-1989 Clinical Pulmonary and Critical Care Fellow
University of California, San Francisco

1989-1991 Pulmonary Research Fellow, San Francisco General Hospital
Cardiovascular Research Institute (CVRI), UCSF

Short-Term Training

2003 IUATLD TB Consultant Course, Cambridge, MA
2005 First DOTS-Plus Consultant Training Course, Riga, Latvia
2008 Infection Control Consultant Training Course, Gaborone,
Botswana

Licensure:

1985-present California license C41907
2004-present Colorado license 42828

Board Certification:

1998-present Board Certified, American Board of Internal Medicine
1990-present Board Certified, Subspecialty Board on Pulmonary Disease
1993-present Critical Care Certification

II. Professional Positions

Academic:

1991-1995 Assistant Adjunct Professor of Medicine, UCSF, Division of
Pulmonary and Critical Care Medicine, SFGH

1995- 1999 Assistant Clinical Professor of Medicine, UCSF,
1999-2004 Associate Professor of Clinical Medicine, UCSF
2004 (Sept 1) Professor of Medicine, National Jewish Medical and Research
Center and University of Colorado Health Sciences Center

Administrative:

1991-2004 Chief, Chest Clinic, San Francisco General Hospital
1993-2004 Medical Director, F. J. Curry National TB Training Center
2002-2004 Associate Program Director, Categorical Medicine, Research and Academic Development, UCSF
2004 (Sept 1) Head, Division of Mycobacterial and Respiratory Infections, National Jewish Medical and Research Center

Clinical:

1987-1993 Attending Physician, Emergency Dept. SFGH
7/87-2004 Attending Physician, Tuberculosis Clinic, San Francisco DPH
7/91-2004 Attending Physician, Medical ICU, SFGH
7/91-2004 Attending Physician, Pulmonary Consult Service, SFGH
2004-present Attending Physician, Division of Mycobacterial and Respiratory Infections

III. Honors and Awards**Undergraduate**

1975-1979 Phi Eta Sigma, AED, Sigma Pi Sigma, Phi Kappa Phi

Medical School

1979-1983 Dean's Scholar, AOA, Alford Memorial Award, Frank Bradley Baker Memorial Award, Sandoz Award, Lange Book Award, Leathers Award, Valedictorian

Awards/Nominations

2003 Nominated for "Great People Award" at UCSF
2002 Best Doctors in San Francisco, San Francisco Magazine
2003 Doctors in San Francisco, San Francisco Magazine
2001-2007 Best Doctors in America

Teaching Awards/Nominations

1992-1993 Nominated for teaching award; "Outstanding Leadership in a Clinical Preceptorship"
1995 Nominated for teaching award, School of Medicine, Class of 1995.
1995-96 First Pulmonary Faculty Teaching Award
2003-04 First Michael S. Stulbarg Outstanding Teaching Award
2000, 2001, 2003 Nominated for UCSF Kaiser Teaching Award (Highest teaching award)

IV. Professional Affiliations**Memberships:**

American Thoracic Society
California Thoracic Society
International Union Against Tuberculosis and Lung Disease
American College Chest Physicians, Fellow

V. Professional Service and Committees

Institutional and Department Committees

National Jewish Medical and Research Center

2006-present Immunology Faculty Search Committee
2006-2007 Faculty Evaluation Sub Committee

University of Colorado Health Sciences Center

2005-2008 Member, CFAR Internal Advisory Board
2005-present Advisory Board, Surgical Center for Infectious Diseases
2005-present Interviewer, Pulmonary/CCM Fellowship Committee
2005-present Interviewer, Infectious Diseases Fellowship Committee

San Francisco General Hospital/Community Health Network

1986-1988 Code Blue Committee, SFGH
1987-1988 Pharmacy and Therapeutics Committee, SFGH
1992-2004 Product Evaluation Committee, SFGH
1995 Community Acquired Pneumonia Practice Guidelines Committee
1995-1997 Co-chairman, Chronic Lung Disease Education Committee, SFGH
1996-2004 Risk Management Subcommittee, SFGH
1998-2004 Community Health Network of SF, Action Group on Guidelines and Practices
1998-1999 Tuberculosis sub-committee, SFGH, co-chair
2002-2004 Education committee

University of California, San Francisco

1992-1994 Grant Reviewer, AIDS Clinical Research, UCSF
1993-2004 Tuberculosis Consultant, UCSF HIV Telephone Consultation Service
1993-2004 Pulmonary Clinical Research Committee, UCSF
1994-2001 Search Committees (AIDS/Onc x3, Occ. Med, ICM, Student Programs)
1996-2004 Categorical Internship Selection Committee, UCSF
2000-2004 Board Member, Clinical Practice Group, Community Health Network
2001-2002 Co-Chair, Clinical X Promotion Guidelines Committee, UCSF
2001-2004 Promotions Sub-Committee for Clinical X Series, UCSF
2002-2004 International Therapeutics Group – HIV
2003-2004 Clinical and Outcomes Research Committee

Professional Organizations

American Thoracic Society

1996-1998 Mycobacterial Drug Susceptibility Working Group
2000-2003 Writing Committee, “Treatment of Tuberculosis”
2000-2007 Microbiology, Tuberculosis, Pulmonary Infections Assembly Program Committee

2003-2004	Program Chair-elect -MTPI Assembly
2004-2005	Program Chair, MTPI Assembly
2003-present	Member, Planning Committee, MTPI Assembly
2005-2006	Chair, Planning Committee, MTPI Assembly
2003-present	Member, Executive Committee, MTPI Assembly
2001-2005	Writing Committee, "Tuberculosis Control in the United States"
2003-2007	Writing Committee, "Management of Nontuberculosis Infections"
2005-present	Co-chair, Writing Committee, "Risk of Mycobacterial and Fungal Infection in Patients Receiving Tumor Necrosis Factor Antagonists"
2006-present	Co-chair, Writing Committee, "Diagnosis and Management of Bronchiectasis"
2007-present	Writing Committee, "Diagnosis of Tuberculosis"
2007-present	Chair-elect, MTPI Assembly
2008-present	Chair, MTPI Assembly
2008-present	Member, Board of Directors, ATS

California Tuberculosis Controllers Association

1994-1998	California Tuberculosis Elimination Implementation Task Force
1997	California Tuberculosis Controllers Association (CTCA), Program Committee
1998-1999	President-elect, CTCA
1999-2000	President, CTCA
2000-2001	Past-President, CTCA

California Thoracic Society

1994-2004	Education Committee, California Thoracic Society (CTS)
1997-2004	Executive Committee, California Thoracic Society
1998	Subcommittee on OSHA TB testimony
1998-2004	Representative for California TB Advisory Committee
1999-2000	Treasurer
2000-2001	Secretary
2001-2002	President-elect
2002-2004	President
2003-2004	Past – President and Chair of Nominating Committee
2001-2004	Chest Disease Scientific Committee, California Medical Association

American Lung Association of California

1995-2004	Tuberculosis Technical Advisory Group (TAG), American Lung Assoc. of California, Chairman, 1995-1999
1998-1999	Chairman, Program Committee for Regional Asthma Conference. Funded by ATS
2001-2002	Finance Committee
2002-2004	Executive Committee and Board Member
2002-2003	Research Program Committee
2002-2003	Government Relations Committee

COPD Foundation

2006-present

Chair, Executive Committee, Bronchiectasis Study Consortium

2007-present

Member, Bronchiectasis Registry Advisory Board

Other

1995

TB/HIV Focus group, California Department of Public Health

Community Service

San Francisco

1986

San Francisco Carnival Celebration Parade, Medical Director

1993-1994

Walter Travel Fund Review Committee, American Lung Assoc.,

SF

National Service

Centers for Disease Control and Prevention

1997

HIV-TB Advisory Group

2001-2005

Core Science Committee- Tuberculosis Clinical Trials Consortium
(review all scientific proposals and protocols)

2001-2003

Research Agenda Committee- Tuberculosis Epidemiology
Consortium (review all scientific proposals and protocols)

2002-2006

Study 27 Protocol Writing Team - Randomized controlled clinical
trial evaluating the difference between 2 month culture status in
smear positive tuberculosis patients randomized to moxifloxacin or
ethambutol plus standard antituberculosis therapy.

2005-present

Member, Nucleic Acid Amplification Working Group

2005-present

Chair, Diagnostics Working Group, TBESC

Other

1994-1998

National Coalition to Eliminate Tuberculosis (NCET)

2004-2006

Observer of record, Subcommittee on Laboratory Diagnosis of
Mycobacterial Infections, NCCLS

2005-present

Chairman, Medical and Scientific Advisory Committee,
Nontuberculous Mycobacterial Information and Research
(NTMIR)

2006

Bronchiectasis Working Group, NHLBI

2006-present

Chair, Steering Committee, Bronchiectasis Research Consortium

International Service

1994

Ad Hoc Grant Reviewer, World Health Organization (WHO)

1998-2000

Problem-based Learning TB Education Work Group, WHO

1999-2002

North American Region of IUATLD, Program Committee, Chair
of Abstract Comm. 1999-2001

2006-present

ATS representative, WHO DOTS-Plus Working Group

2006-present

ATS representative, TBCAP Chest Radiograph Working Group

2007-present

Green Light Committee, Stop TB Partnership- CDC alternate

2007-present

ATS representative, TBCAP MDR-TB Working Group

VI. Patents – None

VII. Review and Referee Activities

Editorial Board

2002-present

American Journal of Respiratory and Critical Care Medicine

Review Services:

AIDS

American Journal of Medicine

American Journal of Public Health

American Journal of Respiratory and Critical Care Med

Annals of Internal Medicine

Archives of Internal Medicine

Chest

Clinical Infectious Diseases

Emerging Infectious Diseases

European Journal of Respiratory Diseases

International Journal of Tuberculosis and Lung Disease

International Journal of Infectious Diseases

Journal of Acquired Immune Deficiency Syndrome

Journal of the American Medical Association

Journal of Antimicrobial Chemotherapy

Journal of Infectious Diseases

Lancet

New England Journal of Medicine

Public Health Reports

Thorax

Tubercle and Lung Disease

Journal of Zoo and Wildlife Medicine

NIH/WHO Review

1995

Ad Hoc Grant Reviewer, WHO

1998

Ad Hoc Grant Reviewer, NIAID

2002

Ad Hoc Grant Reviewer, NIAID

2003

Ad Hoc Grant Reviewer, BTEP

2005

Chairman, Special Study Panel, Fogarty, ICIDR

2007-present

Mid-B Review Section, NIAID, ad hoc

DSMB Activity

2004-present

Chairman, DSMB, NIAID Protocol DMID 03-135, Clinical Trial of Short Course Rifampin vs. INH for LTBI in Jail Populations

2005-present

Chairman, DSMB, NHLBI funded study, Promoting Adherence to TB Regimens in High-Risk Youth

2006-2008

DSMB Member – DMID protocol 03-117, Effect Of Multivitamin Supplements on Immunological and Clinical Response in Childhood Tuberculosis

VIII. Teaching:

A. Graduate and Medical School Lectures

1992-1995	MSIII, "Pneumonia", 1 hour
1995-2004	MSIII, "Tuberculosis", Med 110, 1 hour, 8/year
1993-2004	PharmIII, Clinical Pharmacy, 131, "Tuberculosis"
1995-2004	MSIV, Pathophysiology of Disease, 140.22, "Tuberculosis"
1995-97, 99-01	MSI, Epidemiology and Biostatistics, 101, "Molecular Epidemiology"
1995-2001	Medical Interns, Ambulatory Core Curriculum, "Prevention of TB"
2001-2004	"Molecular Epidemiology", Advanced Training in Clinical Research
2002-2004	MSI - "International Tuberculosis Control"
2003	Doris Duke Research Fellows - "International Health"
2007-present	Mycobacterial Infections (with Marty Voskiul) – Infectious Diseases, IDPT6004, UCHSC
2007-present	Global Epidemiology of Infectious Diseases, MICB 7704, UCHSC

B. Medical Student Preceptor

1995	ICM 131A
1989, 90, 92	ICM 132A

C. Predoctoral Students Supervised

1995-1996	Kathy DeRiemer, MPH student, UC Berkeley
1997	Stephanie Cuthbert, Medical Student, Melbourne, Australia
1998	Ada Wong, Medical Student, University of Iowa
1998-1999	Lisa Giese, Medical Student, UCSF
2001	Chris Seaman, Undergraduate, Vassar
2002	Alon Unger, UCSF

D. Postdoctoral Fellows Supervised

1995-196	Marcus Conde, MD, Fogarty Fellow, Universidad do Federal, Rio De Janeiro, Brazil
2000	Elad Ziv, MD, Medical Resident, UCSF
1999-2001	Pratima Singh, MD, MSc student, San Francisco State
1999-2002	Marcos Burgos, MD, Fogarty Fellow, Columbia/US
2000-2003	Adrian Ong, MD, Fogarty Fellow, Singapore
2001	Wee Pek, MD, Pulmonary Fellow, Singapore
2000-2002	Ivan Sabogal, MD, Fogarty Fellow, Peru
2001-2003	Ted Marras, MD, MPH, Pulmonary Fellow, Toronto University
2003	Ai Ching Kor, MD, Pulmonary Fellow Singapore
2004	Payam Nahid, MD, MPH, Pulmonary Fellow, UCSF
2005-2007	Carlos Perez Velez, MD, ID Fellow, UCHSC
2006-2007	Shannon Kasperbauer, ID Fellow, UCHSC
2006-present	Maxine Dexter, MD, Pulmonary Fellow, UCSHC
2007-present	Julie Jarand, MD, Post-doc, Univ. of Calgary, Alberta
2008-present	Brendan Clarke, MD, Pulmonary Fellow, UCSHC

E. Informal Teaching - Attending Physician

1987-1991	General Medicine wards
1987-2004	San Francisco Tuberculosis Clinic
1991-2004	Pulmonary Consult Service
1991-2004	Medical Intensive Care Unit

F. Other Teaching Activities

Approximately 5-10 lectures/year to the various housestaff (noon conferences)

1996-1998	Workshop leader for "AIDS in Africa", Annual UCSF Student AIDS Forum
1990-1992	Medical Consultant, Muhimbili Medical Center, Dar es Salaam, TZ
1900-1992	Taught chest radiography to medical students at Muhimbili

IX. Research Grants and Contracts

Current Research Grant/Contract

200-2001-00079, Task Order #6 (subcontract - Daley) CDC Regional Capacity Building in Low Incidence Areas	04/07/03 – 04/07/08 \$595,238/year
Task Order #18, CDC Contract (Daley PI, subcontract) Evaluation of Interferon-gamma release assays in Health Care Workers	08/06-08/10 \$4,500,000
R13 AI066889 (Daley PI) NIH/NIAID Advances in Nontuberculous Mycobacterial Infections	07/01/06-06/30/07 \$11,058
R34 1R34AI72271-01 (Daley PI) NIH/NIAID NTM Clinical Trials Consortium	9/1/06-8/31/07 \$247,000
Exxon-Mobil Training Program for Former Soviet TB Controllers	2005-2007 \$40,000

Completed or Left Behind When Leaving UCSF

5 R01 AI34238-11 (Hopewell- PI, Daley acting PI 2003-04) NIH/NIAID Population Based Molecular Epidemiology of Tuberculosis	07/01/93 – 08/30/06 \$954,288/year
2000-1999-00098 (Daley) CDC Tuberculosis Trials Consortium	09/23/99 – 09/22/09 \$291,416/year
N01 AI95383 (prime: Case Western Reserve University) NIH/NIAID UCSF subcontract (Daley/Hopewell) Tuberculosis Prevention Research Network	12/01/99 – 11/30/06 \$164,751/year

200-2001-00079 (Daley) CDC Tuberculosis Epidemiological Studies Consortium	09/29/01 – 09/28/11 \$130,362/year
U52/CCU900454 (prime: City & County of San Francisco) CDC UCSF subcontract (Hopewell/Daley) Model Tuberculosis Prevention and Control Center	01/25/94 – 12/31/04 \$1,854,798/year
POHC04000575 (Daley) City and County of San Francisco Tuberculosis Clinic Physicians Services	07/01/03 – 06/30/04 \$228,000/year
POHC04000583 (prime: City & County of San Francisco) CDC (UCSF subcontract (Daley) Evaluation of the QuantiFERON TB Test	01/01/00 – 12/31/04 \$141,164
Mesosystems, NIAID SBIR (Daley) Assessment of Gas Sampling Device for Detection of <i>M. tuberculosis</i>	2002-2005 \$21,000
K07 (Daley) NHLBI Tuberculosis Academic Award	1994-99 \$75,000/year
Cooperative Agreement (Daley) CDC Evaluation of QuantiFERON	1998-99 \$80,000
D43 TW00905 (PI – Lee Riley, subcontract to Daley) NIH/Fogarty International Tuberculosis Training Grant	1998-6/2004 \$125,000/year
Contract (Daley) CDC Rifampin Monoresistance in San Francisco Bay Area	1998-99 \$60,000/yr
Contract (Daley) InterMune Pharmaceuticals, Inc Interferon gamma-1b for Pulmonary Disease due to MAC - PI	2000-02 \$5000/patient

Bibliography

A. Refereed journals:

1. Goodman PC, Daley CL, Minagi H. Spontaneous pneumothorax in AIDS patients with *Pneumocystis carinii* pneumonia. *AJR* 147:29-31, 1986.
2. Daley CL. Adjuvant therapy of bacterial meningitis: Assessment by Delphi group opinion technique. *Ped Inf Dis J*. 6:1160-1, 1987.
3. Daley CL, Schechter G. Tuberculosis outbreak among residents in a residential facility for HIV infected persons. *MMWR* 40:649-652, 1991.
4. Greenman RL, Schein RMH, Martin MA, Wenzel RP, Emmanuel G, et al (Daley). A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. *JAMA* 266:1097-1102, 1991.
5. Daley CL, Small PM, Schechter GF, Schoolnik GK, McAdam RA, Jacobs WR, Hopewell PC. Transmission and accelerated progression of tuberculosis in patients infected with the human immunodeficiency virus: Characterization of an outbreak using restriction fragment length polymorphism analysis. *N Engl J Med* 1992;326:321-325.
6. Janoff E, Breiman R, Daley CL, Hopewell P. Pneumococcal disease during HIV infection: Epidemiologic, clinical, and immunologic perspectives. *Ann Intern Med* 117:314-324, 1992.
7. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, Schechter GF, Daley CL, Schoolnik GK. The contemporary urban epidemiology of tuberculosis: A population-based study using conventional and molecular methods. *N Engl J Med* 330:1703-9, 1994.
8. Mlika-Cabanne N, Brauner M, Mugusi F, Grenier P, Daley C, Mbaga I, Larouze B, Murray JF. Radiographic abnormalities in tuberculosis and risk of coexisting HIV infection: Results from Dar es Salaam, Tanzania, and scoring system. *Am J Resp Crit Care Med* 152:786-793, 1995 .
9. Opstad NL, Daley CL, Thurn JR, Rubins JB, Merrifield C, Hopewell PC, Janoff EN. Impact of *Streptococcus pneumoniae* bacteremia and HIV-1 infection on oral mucosal immunity. *J Infect Dis* 172:566-70, 1995.
10. Amdahl BM, Rubins JB, Daley CL, Gilks C, Hopewell PC, Janoff EN. Impaired natural immunity to pneumolysin in HIV-infected patients in the United States and Africa. *Am J Respir Crit Care Dis* 152:2000-4, 1995
11. Casper C, Singh SP, Rane S, Daley CL, Schechter GS, Riley LW, Kreiswirth BN, Small PM. Transcontinental transmission of tuberculosis: a molecular epidemiological assessment. *Am J Pub Health* 86:551-553, 1996
12. Daley CL, Mugusi F, Chen L, et al. Pulmonary complications of HIV infection in Tanzania: role of bronchoscopy and bronchoalveolar lavage. *Am J Respir Crit Care Med* 154:105-110, 1996
13. Vanham G, Edmonds K, Qing L, Hom D, Toossi Z, Jones B, Daley C, Huebner R, Kestens L, Gigase P, Ellner J. Global immune activation in pulmonary tuberculosis: synergism with concurrent HIV infection. *Clin and Exp Immunology* 103:30-4, 1996
14. Samb B, Henzel D, Daley CL, et al. Methods for diagnosing tuberculosis among inpatients in eastern Africa whose sputum smears are negative. *Intern J Tuberc Lung Dis*. 1:25-30, 1997.
15. Daley CL, Hahn JA, Moss A, Hopewell PC, Schechter GF. Incidence of tuberculosis in injection drug users in San Francisco. *Am J Respir Crit Care Med* 157:19-22, 1998.
16. Yeh RW, Ponce de Leon A, Agasino CB, Hahn J, Daley CL, Hopewell PC, Small PM. Genotype stability in serial secretors of *M. tuberculosis* in San Francisco. *J Infect Dis* 1998;177:1107-11.

17. Chin DP, De Riemer K, Small PM, Ponce de Leon A, Steinhart R, Schechter GF, **Daley CL**, Moss Ar, Paz A, Jasmer RM, Agasino CB, Hopewell PC. Interaction of factors contributing to the incidence of tuberculosis in San Francisco. *Am J Respir Crit Care Med* 1998;158:1797-1803
18. DeRiemer K, **Daley CL**, Reingold AL. Preventing tuberculosis among HIV-infected persons: a survey of physicians' knowledge and practices. *Preventive Medicine* 1999;28:437-444.
19. DeRiemer K, Schechter GF, Hopewell PC, **Daley CL**. Epidemiology of tuberculosis diagnosed at death in San Francisco. *Internat J Tuberc Lung Dis* 1999;3:488-493.
20. Yeh RW, Hopewell PC, **Daley CL**. Simultaneous infection with two strains of *M. tuberculosis* identified by restriction fragment length polymorphism analysis. *Internat J Tuberc Lung Dis* 1999;3:537-539.
21. Behr MA, Warren SA, Ponce de Leon A, Salamon H, **Daley CL**, Hopewell PC, Small PM. Infectivity of AFB smear-negative tuberculosis patients in San Francisco. *Lancet* 1999;353:444-449.
22. Jasmer RM, Hahn J, Small PM, **Daley CL**, et al. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. *Ann Intern Med* 1999;130:971-978.
23. Moss AR, Hahn JA, Tulksy JP, **Daley CL**, Small PM, Hopewell PC. Tuberculosis in the homeless: a prospective study. *Am J Respir Crit Care Med* 2000;162:460-464.
24. Jasmer RM, Snyder DC, Chin DP, Cuthbert SS, Paz EA, Hopewell PC, **Daley CL**. Twelve months of isoniazid compared to four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost effectiveness analysis. *Am J Respir Crit Care Med* 2000;162:1648-1652.
25. Conde MB, Soares SLM, Mello FQ, Rezende VM, Almeida LL, Reingold A, **Daley CL**, Kritski AL. Prospective comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis. Experience at an AIDS reference center in Rio de Janeiro, Brazil. *Am J Respir Crit Care Med* 2000;162:2238-2240.
26. Ziv E, **Daley CL**, Blower S. Early therapy for latent infection. *Am J Epidemiol* 2001;154:381-385.
27. Mazurek G, LoBue P, **Daley CL**, et al. Comparison of *QuantiFERON®-TB* with tuberculin skin testing for detecting latent *Mycobacterium tuberculosis* infections in the United States. *JAMA* 2001;286:1740-1747.
28. Pai M, McCulloch M, Reingold AL, **Daley CL**, Riley LW, Colford JM. Duration of therapy for tuberculosis in patients infected with Human Immunodeficiency Virus (Protocol for a Cochrane Review). In: *The Cochrane Library*, Issue 3, 2002.
29. Jasmer RM, Saukkonen JJ, Blumberg HM, **Daley CL**, Bernardo J, Vittinghoff E, King MD, Kawamura M, Hopewell PC. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter prospective, randomized, controlled trial. *Ann Intern Med* 2002;137:640-647.
30. Conde MB, Loivos AC, Rezende VM, Soares SLM, Mello FCQ, Reingold AL, **Daley CL**, Kritski AL. The yield of sputum induction in the diagnosis of pleural tuberculosis. *Am J Respir Crit Care Med* 2003;167(5):723-5.
31. Blumberg HM, Burman WJ, **Daley CL**, et al. Treatment of tuberculosis. *Am J Respir Crit Care Med* 2003;167:604-662.
32. Burgos M, DeReimer K, Small PM, Hopewell PC, **Daley CL**. Impact of drug-resistance on the generation of secondary cases of tuberculosis. *JID* 2003;188:1878-1884.
33. Ong A, Creasman J, Hopewell PC, Gonzalez L, Wong M, Jasmer RM, **Daley CL**. A molecular epidemiologic assessment of extrapulmonary tuberculosis in San Francisco. *CID* 2004;38: 25-31.

34. Jasmer RM., Snyder DC, Saukkonen JJ, Blumberg H, Hopewell PC, Bernardo J, King MD, Kawamura LM, **Daley CL**, for the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-Course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A Cost-Effectiveness analysis based on a multicenter clinical trial. *CID* 2004; 38: 363-9.
35. Marras TK, **Daley CL**. *Mycobacterium kansasii* infection in human immunodeficiency virus infected individuals . *J of Acq Immun Def* 2004;36:883-889.
36. Ziv E, **Daley CL**, Blower S. Potential public health impact of tuberculosis vaccines. *Emerg Infect Dis* 2004;10:1529-1535.
37. Jasmer RM, Seaman C, Gonzalez LC, Kawamura LM, **Daley CL**. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. *Am J Respir Crit Care Med* 2004;170:561-566.
38. Marras TK, Gonzalez L, **Daley CL**. Predictors of mortality in HIV-infected patients with pulmonary *Mycobacterium kansasii*. *Am J Respir Crit Care Med* 2004;170:793-798.
39. Marras TK, Wallace RJ, Koth LL, Stulbarg MS, Cowl CT, **Daley CL**. Hypersensitivity pneumonitis reaction to *Mycobacterium avium* in household water. *Chest* 2005;127:664-671.
40. Burgos M, Gonzalez LC, Paz EA, Gournis E, Kawamura M, Schechter G, Hopewell PC, **Daley CL**. Treatment of multi-drug resistant tuberculosis in San Francisco: An outpatient-based approach. *CID* 2005;40:968-975.
41. Pai M, Gokhale K, Hoshi R, Dogra S, Shriprakash K, Mendiratta DK, Narang P, **Daley CL**, Granich RM, Mazurek GH, Reingold AL, Riley LW, Colford JM. *Mycobacterium tuberculosis* infection in health care workers in rural India: comparison of a whole-blood, interferon-gamma assay with tuberculin skin testing. *JAMA* 2005;293:1-10.
42. Ong A, Rudoy I, Creasman J, Gonzalez L, Kawamura M, **Daley CL**. Tuberculosis in health care workers - A molecular epidemiologic study. *Hosp Epid Infect Control* 2006;27:453-8.
43. Cattamanchi A, Jasmer RM, Gonzalez BA, Osmond D, Kawamura LM, **Daley CL**, Hopewell PC. A thirteen-year molecular epidemiology analysis of tuberculosis in San Francisco: time for a reappraisal of control measures? In *J of TB Lung Dis* 2006;10:297-304.
44. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, **Daley CL**, Catanzaro A. Factors related to response to intermittent treatment of *Mycobacterium avium* complex lung disease. *Am J Respir Crit Care Med* 2006; 173:1283-9.
45. Johnson JL, Hadad DJ, Boom HW, **Daley CL**, et al. Early and extended bactericidal activity of levofloxacin, gatifloxacin, and moxifloxacin in pulmonary tuberculosis. *Int J of TB Lung Dis* 2006;10:605-612.
46. Burman WL, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher M, Choudhri S, **Daley CL**, Munsiff S, Zhao Z, Vernon A, Chaisson R. An evaluation of the activity and tolerability of moxifloxacin during the first two months of treatment for pulmonary tuberculosis. *Am J Respir Crit Care Med* 2006;174:331-338.
47. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, **Daley C**...An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. *Am J Respir Crit Care Med* 2007;175:367-416.
48. Nahid P, Gonzalez L, Rudoy I, de Jong B, **Daley CL**. Treatment outcomes for HIV-related tuberculosis in San Francisco. *Am J Respir Crit Care Med* 2007;17:1199-1206.
49. Wu B, Huang C, Kato-Maeda M, Hopewell PC, **Daley CL**, Krensky AM, Clayberger C. Messenger RNA expression of IL-8, FOXP3, and IL-12 beta differentiates latent tuberculosis infection. *J of Immunol. J Immunol* 2007;178:3688-94.

50. DeRiemer K, Kawamura M, Hopewell PC, **Daley CL**. Quantitative impact of human immunodeficiency virus infection on tuberculosis dynamics. *Am J Respir Crit Care Med* 2007;176:936-944.
51. Mazurek GH, Weis SE, Moonan PK, **Daley CL**, Bernardo J, Lardizabal AA, Reves RR, Tony SR, Daniels LJ, LoBue PA. Prospective comparison of tuberculin skin test and two-whole blood interferon-gamma release assays in tuberculosis suspects. *CID* 2007;45:837-845.
52. Boulware DR, **Daley CL**, Merrifield C, Janoff EN. Rapid diagnosis of *Streptococcus pneumoniae* infection among HIV infected adults with urine antigen detection and C-reactive protein. *J of Infect* 2007;55:300-309.
53. Wu B, Huang C, Kato-Maeda M, Hopewell PC, **Daley CL**, Krensky AM, Clayberger C. IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. *Clin Immunol* 2007;126:202-210.
54. Cattamanchi A, Nahid P, Marras TK, Gotway MB, Lee TJ, Gonzalez LC, Morris A, Webb WR, Osmond DH, **Daley CL**. Detailed analysis of the radiographic presentation of *Mycobacterium kansasii* lung disease in HIV-infected patients. *Chest* Feb 8, 2008, epub ahead of print.
55. Wu B, Huang C, Kato-Maeda M, Hopewell PC, **Daley CL**, Krensky AM, Clayberger C. IL-24 modulates IFN-gamma expression in patients with tuberculosis. *Immunology Letters*. 2008;117:57-62.

B. Book Chapters and Reviews:

Invited Reviews:

1. **Daley CL**, Sande MA. The Runny Nose: Infection of the paranasal sinuses. *Infectious Dis Clin of N Amer.* 2:131-147, 1988.
2. **Daley CL**. Pyogenic bacterial pneumonia in the acquired immunodeficiency syndrome. *J Thorac Imaging* 6:36-42, 1991.
3. **Daley CL**. Pulmonary infections in the tropics: Impact of HIV infection. *Thorax* 49:370-378, 1994.
4. **Daley CL**. Bacterial pneumonia in HIV infected patients. *Seminars in Respiratory Infection* 8:104-115, 1993.
5. Salfinger M, Hale YM, **Daley CL**. Drug-resistant tuberculosis. *RT.* 10:85-93, 1997.
6. Bradford WZ, **Daley CL**. Multidrug-resistant tuberculosis. *Infectious Disease Clinics of North America.* 1997; 157-172.
7. Marras T, **Daley CL**. Epidemiology of nontuberculous mycobacteria. *Chest Clinics of North America.* 2002;23:623-632.
8. Griffith D, **Daley CL**. Management of lung disease due to rapidly growing mycobacteria. *Chest Clinics of North American.* 2002;23: 553-567.
9. **Daley CL**, Kawamura ML. The role of molecular epidemiology in contact investigations: a U.S. perspective. *Int J Tuber Lung Dis* 2003;7 (Suppl 3):S458-62.
10. DeRiemer K, **Daley CL**. Molecular Epidemiology of Tuberculosis. *Seminars in Respiratory and Critical Care Medicine.* Ed Heifets L. 2004;25:297-306.
11. **Daley CL**. Molecular Epidemiology. *Chest Clinics of North American.* 2005;26:217-31.
12. Nahid P, **Daley CL**. Prevention of tuberculosis in HIV infected patients. *Current Opinions in Infectious Diseases* 2006;19:189-193.
13. Daley CL. Treatment of *M. avium* complex pulmonary infections. *Chest Clinics of North America* (2008)
14. Schiesow J, **Daley CL**. Moxifloxacin. *Future Drugs* (in press).

Book Chapters:

1. **Daley CL**, Hollander H. The Acquired Immunodeficiency Syndrome. In: Skach B, Daley CL, Forsmark CE, eds, Handbook of Medical Treatment. Jones Medical Publications, 18th edition, 1988: 397-424.
2. Noble P, **Daley CL**, Brown JK. Respiratory Diseases. In: Skach B, Daley CL, Forsmark CE, eds, Handbook of Medical Treatment. Jones Medical Publications, 18th edition, 1988:78-101.
3. **Daley CL**, Sande MA. Outpatient acquired pneumonia. In: Stein JH, ed, Internal Medicine. Little, Brown, and Co, 2nd edition, 1990.
4. **Daley CL**. AIDS in Africa. In Cohen PT, Sande M, Volberding P, eds, The AIDS Knowledge Base. Little-Brown, 2nd ed., 1990.
5. **Daley CL**. Encapsulated bacteria in HIV infection. In Cohen PT, Sande M, Volberding P, eds, The AIDS Knowledge Base. Little-Brown, 2nd ed., 1990.
6. **Daley CL**. Current issues in the pathogenesis and management of tuberculosis. In Volberding PA, Jacobson MA, AIDS Clinical Review. Marcel Dekker. 1998, pg 289-321.
7. **Daley CL**. Tuberculosis. Antimicrobial Therapy and Vaccines. Ed. Nu, V. 1st ed. 1998, pg. 521-541.
8. **Daley CL**. AIDS in Africa. In Cohen PT, Sande M, Volberding P, eds, The AIDS Knowledge Base. Little-Brown, 3rd ed., 1997.
9. **Daley CL**. Pneumococcal disease in HIV infection. In Cohen PT, Sande M, Volberding P, eds, The AIDS Knowledge Base. Little-Brown, 3rd ed., 1997.
10. **Daley CL**, Hopewell PC. Tuberculosis. Hospital Medicine. Ed Wachter, Hollander, Goldman. 1st ed. 1999.
11. **Daley CL**. Tuberculin Skin Testing. Clinics Atlas to Office Procedures, 1999.
12. **Daley CL**. Pulmonary Tuberculosis. Kelley's Textbook of Internal Medicine. Ed Humes HD, Fourth ed. 1999.
13. **Daley CL**. Tuberculosis and HIV. In Cohen PT, Sande M, Volberding P, eds, The AIDS Knowledge Base. Internet Text. 2003
14. **Daley CL**. Latency. In Rom and Garay, 2nd ed. of Tuberculosis. 2004
15. **Daley CL**. Tuberculosis. Antimicrobial Therapy and Vaccines. Ed. Nu, V. 2nd ed. 2003
16. DeReimer K, **Daley CL**. Molecular Epidemiology of Tuberculosis in Tuberculosis Ed Madkour MM. 1st ed. 2003.
17. **Daley CL**, Gotway M, Jasmer R. Radiographic Manifestation of Tuberculosis. A primer for clinicians. 1st ed. 2003.
18. **Daley CL**. Treatment of Latent Tuberculosis Infection. Yew WW in 2007.
19. **Daley CL**. Nontuberculous Mycobacterial Infections. Bacterial Infections in Humans. 4th ed., eds Brachman and Abrutyn. Springer Pub. New York, NY (in press)
20. **Daley CL**. Latent Tuberculosis Infection. A Clinicians Guide to Tuberculosis. 2nd ed. Iseman and Daley. Lippincott Williams & Wilkins. Philadelphia. Scheduled for publication in 2006. (In press)
21. **Gotway M, Daley CL**. Radiographic Manifestations of Tuberculosis. Tuberculosis- a comprehensive clinical treatise. 1st ed. Zumla and Schaaf. (in press)
22. **Daley CL, Heifets L**. Nontuberculous Mycobacteria. Tuberculosis- a comprehensive clinical treatise. 1st ed. Zumla and Schaaf. (in press)
23. **Daley CL**. Tuberculosis and Nontuberculous Mycobacteria. Clinical Respiratory Medicine, 3rd ed. Eds Albert, Spiro, and Jett. Elsevier. (in press)

24. **Daley CL.** Molecular Epidemiology of Tuberculosis. 2nd ed. Tuberculosis, PD Davies. (in press)
25. Kasperbauer SH, **Daley CL.** Diagnosis and Treatment of Infections due to Mycobacterium avium complex. Seminars in Respiratory and Critical Care Medicine. (in press).
26. **Daley CL** and Griffith D. Nontuberculous Mycobacterial Infections. Murray and Nadel (in prep)

C. Other publications

Editorials/Commentaries/Letters:

1. **Daley CL.** Tuberculosis recurrences in Africa: relapse or reinfection? *Lancet* 342:756-757, 1993.
2. **Daley, CL.** The typically “atypical” radiographic presentation of tuberculosis in advanced HIV disease. *Tubercle and Lung Dis* 76:475-76, 1995.
3. **Daley, CL.** Transmission of multidrug-resistant tuberculosis: Limited by man or nature? *Am J Respir Crit Care Med* 2002;165:742-743.
4. **Daley CL,** Blower S. Problems and solutions for the Stop TB Partnership. *Lancet-Infectious Diseases* 2002;2:374-6.
5. **Jasmer R, Daley CL.** Rifampin and Pyrazinamide: Is it Safe? *Am J Respir Crit Care Med* 2003;167:809-812.
6. **Daley CL.** Tuberculosis Contact Investigations: Please don’t fail me now. *Am J Respir Crit Care Med* 2004;169:779-81.
7. Mazurek GH, LoBue PA, **Daley CL,** et al. Detection of Mycobacterium tuberculosis infection by whole-blood interferon-gamma release assay (letter). *Clin Infect Dis* 2003;36:1207-1208.
8. Burgos M, DeRiemer K, Small PM, Hopewell PC, **Daley CL,** Reply. *J Infect Dis.* 2004;190:650-651.
9. Burgos M, Deriemer K, Small PM, Hopewell PC, **Daley CL.** Reply. *J Infect Dis.* 2005 1;191(5):824.
10. Winthrop K, **Daley CL,** Griffith D. Nontuberculous mycobacterial disease: updated diagnostic criteria for an under-recognized infectious complication of anti-tumor necrosis factor therapy. *Nature Clin Practice Rheum* 2007;3;E1.
11. Winthrop K, **Daley C.** A novel assay for screening patients for latent tuberculosis infection prior to anti-tumor necrosis factor therapy. *Nature Clin Practice Rheum* 2008. (in press)

Editing:

1. Handbook of Medical Treatment. Skach B, **Daley CL,** Forsmark.CE, eds. 18th ed. 1988.
2. Seminars in Respiratory Infection. Pulmonary Complications of HIV Infection. Guest Editor: **CL Daley.** June 1993.
3. Nontuberculous Mycobacteria; Clinics in Chest Medicine. **Daley CL,** Catanzaro A, eds Sept. 2002;23;529-694.
4. **Daley CL,** Gotway M, Jasmer R. Radiographic Manifestation of Tuberculosis. A primer for clinicians. 1st ed.
5. Drug-resistant Tuberculosis. A Survival Guide for Clinicians. 2008, 2nd edition.

CDROM and Internet:

1. Tuberculosis: An interactive guide for clinicians. Medical Consultant, 1998. Award for Outstanding Course Production from California Distance Learning Health Network.

2. Featured Case, Medical Consultant, 1998-present. Interactive case on Curry National TB Centers web page (www.nationaltbcenter.edu).
3. TB and HIV: An Online Course for Clinicians (www.nationaltbcenter.edu)
4. **Daley CL**, Gotway M, Jasmer R. Radiographic Manifestation of Tuberculosis. A primer for clinicians. 1st ed, in 2nd printing (www.nationaltbcenter.edu)

D. Abstracts (selected):

1. **Daley CL**. Adjuvant therapy of bacterial meningitis: assessment by Delphi group opinion technique. Presented at a symposium on bacterial meningitis in La Costa, CA. 1988.
2. **Daley CL**, Small PM, Schechter G, et al. Characterization of an outbreak of tuberculosis using RFLP analysis. Presented at the American Federation for Clinical Research, Carmel, CA, Feb. 7, 1992.
3. **Daley CL**, Steinhart R, Reingold A, Hopewell PC. Development of a mechanism to identify preventable tuberculosis cases. *Am Rev Respir Dis* 145:A223, 1992.
4. **Daley CL**, Fennelly K, Stansell J, et al. Nontraumatic pneumothorax in HIV infected patients. *Am Rev Respir Dis* 145:A821, 1992
5. **Daley CL**, Chen L, Mugusi F, et al. Pulmonary complications of HIV infection in Tanzania. *Am Rev Respir Dis* 145:A821, 1992.
6. Janoff E, **Daley CL**, et al. Pneumococcal meningitis in the modern era. International Conference on Antimicrobial and Chemotherapeutic Agents, Anaheim, CA, 1992.
7. Janoff E, **Daley CL**, et al. Immunoglobulin response to pneumococcal disease in HIV infected patients. International Conference on Antimicrobial and Chemotherapeutic Agents, Anaheim, CA, 1992.
8. Janoff EN, **Daley CL**, Zhai Y, et al. Acute phase responses to *Streptococcus pneumoniae* are intact in HIV-infected patients. AAI/CIS meeting, 1993.
9. Villarino M, Geiter L, Hopewell P, **Daley C**, Rudoy I, Lyle M. Parameters of cell-mediated immunity (CMI) in tuberculosis patients with human immunodeficiency virus (HIV+) and without HIV (HIV-) coinfection. *Am Rev Respir Dis* 147:A216, 1993.
10. Mlika-Cabanne N, Brauner M, Grenia P, Kamanfu G, **Daley C**, Aubry P, Mbaga I, Murray JF. Radiographic findings in HIV-seropositive and seronegative African patients with tuberculosis and derivation of a score to predict serologic status. *Clinical Research*, Washington 1994, pp 280A.
11. Ruston DC, Small PM, Paz T, Schoolnik G, **Daley C**, Hopewell P. Investigation of a cluster of TB patients: Molecular vs conventional epidemiology. *Am Rev Respir Dis* 149:A526, 1994.
12. **Daley CL**, Rudoy I, Small PM, Schechter GF, Hopewell PC. Efficacy of a 6-month regimen in the treatment of tuberculosis in HIV infected patients. abstract #29. *Tubercle and Lung Disease* 75:8, 1994.
13. **Daley CL**, DeReimer K, Small PM, Schechter GF, Hopewell PC. Tuberculosis diagnosed at death in San Francisco. *Am J Respir Crit Care Med* 151:A147, 1995.
14. Chin DP, DeReimer K, Small PM, Schechter GF, **Daley CL**, Hopewell PM. Recent transmission and reactivation of *Mycobacterium tuberculosis* among foreign-born persons in San Francisco. *Am J Respir Crit Care Med* 151:A666, 1995.
15. **Daley CL**, Rudoy I, Schechter GF, Hopewell PC. CD4 lymphocyte count before and after treatment for tuberculosis. Presented at Lancet TB Conf. Washington, D.C., 9/95
16. **Daley CL**, Hahn J, Moss A, Schechter GF. Risk of tuberculosis in anergic injection drug users. *Tubercle and Lung Dis.* 76:137, 1995.

17. Samb B, **Daley CL**, Niyongabo T, et al. Clinical features of pulmonary tuberculosis among smear negative patients in East Africa. *Tubercle and Lung Dis.* 76:143, 1995.
18. **Daley CL**, Small PM, Ponce de Leon, et al. Tuberculosis recurrences in San Francisco: Relapse or reinfection. *Am J Respir Crit Care Med* 153:A110, 1996.
19. **Daley CL**, Bibbins-Domingo K, Ponce de Leon, et al. Laboratory cross-contamination of *M. tuberculosis* cultures: a disappearing phenomenon in San Francisco. *Am J Respir Crit Care Med* 153:A36, 1996.
20. Hahn J, Zolopa A, Tulsy J, **Daley CL**, Small P, Hopewell P, Moss A. Incidence of active tuberculosis in a population based sample of homeless persons in San Francisco. *Am J Respir Crit Care Med* 153:A132, 1996.
21. **Daley CL**, DeReimer K, Hopewell PC. Tuberculosis transmission among HIV-infected persons. *Am J Respir Crit Care Med* 155:A225, 1997.
22. Jasmer RM, Hahn J, Hopewell PC, **Daley CL**, Moss AR, Small PM. Trends of transmission of *M. tuberculosis* in San Francisco. *Am J Respir Crit Care Med* 155:A227, 1997.
23. Soares SLM, Mello FCQ, Rezende VMC, Conde MB, Pinheiro MCAC, Almeida LL, Reingold A, **Daley C**, Kritski A. Characteristics of 151 respiratory symptomatic patients suspected of having pulmonary tuberculosis in Rio de Janeiro, Brazil. *Am J Respir Crit Care Med* 157:A573, 1998.
24. Mazurek GH, LoBue PA, Lardizabal AA, Bernardo J, **Daley CL**, Bishai WR, Rothel JS. Comparison of QuantiFERON-TB and tuberculin skin testing. *The International Journal of Tuberculosis and Lung Disease*;3(Suppl 1); S184, 1999.
25. Jasmer RM, Snyder CD, Cuthbert S, Chin DP, Paz PC, Hopewell PC, **Daley CL**. Isoniazid compared to isoniazid and rifampin for previous tuberculosis (TB-4): An outcome and cost-effectiveness analysis. *Am J Respir Crit Care Med* 161:A253, 2000.
26. Martinez AN, Bradford WZ, Agasion CB, Paz T, **Daley CL**. Outbreak of rifampin mono-resistant (RMR) tuberculosis (TB) in San Francisco. *Am J Respir Crit Care Med* 161:A304, 2000.
27. Jasmer RM, Bernardo J, **Daley CL**, Merrifield C, Blumberg HM, Saukkonen JJ, Stringer HG, Hopewell PC. Short course rifampin and pyrazinamide versus isoniazid for latent tuberculosis infection: a multicenter, prospective, randomized, controlled trial. *Am J Respir Crit Care Med* 161:A524, 2000.
28. Creasman JM, Hopewell PC, Small PM, **Daley CL**. Cluster dynamics of *M. tuberculosis* in San Francisco. *Am J Respir Crit Care Med* 161:A896, 2000.
29. Martinez AN, **Daley CL**. Epidemiology of rifampin mono-resistant tuberculosis in San Francisco. *Am J Respir Crit Care Med* 161:A897, 2000.
30. Ong A, Creasman J, Rudoy I, **Daley CL**. Epidemiology of tuberculosis among health care workers. *Am J Respir Crit Care Med* 163:A965, 2001
31. Jasmer RM, Snyder DC, Saukkonen JJ, Blumberg HM, Bernardo J, King M, Hopewell PC, Kawamura LM, **Daley CL**. Short course rifampin and pyrazinamide versus isoniazid for latent tuberculosis infection: A Cost-effectiveness analysis based on a multicenter randomized trial. *Am J Respir Crit Care Med*, 2002;165:A17.
32. Burgos M, DeReimer K, Small PM, Hopewell PC, **Daley CL**. Relative fitness of drug-resistant and drug-susceptible strains of *M. tuberculosis* in San Francisco. *Am J Respir Crit Care Med*, 2002;169:A18.
33. Burgos M, Paz A, Schechter G, Hopewell PC, Kawamura M, **Daley CL**. Treatment of multi-drug resistant tuberculosis. *Am J Respir Crit Care Med*, 2002;169:A715.
34. Ong A, Creasman J, Wong M, Hopewell P, **Daley CL**. Molecular epidemiology of extrapulmonary tuberculosis. *Am J Respir Crit Care Med* 2002;165:A439.

35. Marras T, Gonzalez LC, **Daley CL**. Pulmonary *Mycobacterium kansasii* infection in human immunodeficiency virus infected individuals: diagnostic criteria and treatment in predicting survival. *AJRCCM* 2003;167:A708.
36. Jasmer RM, Seaman C, Gonzalez LC, Kawamura LM, **Daley CL**. Treatment outcomes among tuberculosis patients treated by directly observed therapy compared with self-administered therapy. *AJRCCM* 2003;167:A868.
37. Berger DM, Nolan C, Reves R, **Daley CL**. Conducting a TB Program Assessment to Identifying Regionalization Opportunities. IUATLD-NAR Annual Conference, Austin, February 26-28, 2004.
38. Spradling P, Bozeman L, Metchock B, Burman W, Chaisson D, **Daley C**, Engle M, Arevalo B, Johnson J, Moser A, Choudhri S, Munsiff S, OBrien R, Vernon A, Zhao Z, and the TBTC. Fluoroquinolone resistance among pre-treatment *Mycobacterium tuberculosis* isolates in an international multicenter randomized clinical trial. Accepted for ATS, San Diego, 2005.
39. Cattamanchi A, Jasmer RM, Gonzalez BA, Osmond D, Kawamura LM, **Daley CL**, Hopewell PC. A thirteen-year molecular epidemiology analysis of tuberculosis in San Francisco: time for a reappraisal of control measures? ATS, San Diego, 2005.
40. Burman WJ, Goldberg S, Johnson J, Muzanye G, Mosher A, Engle M, Shurjeel Choudri, Munsiff S, **Daley CL**, Borisov A, Chaisson RE, Vernon A. Effect of HIV infection on the Initial Bacteriologic Response to Treatment of Pulmonary Tuberculosis. IDSA, Toronto, 2006.
41. Dexter M, Heifets L, **Daley CL**. Fluoroquinolone resistance in *M. tuberculosis*. *Am J Respir Crit Care Méd* 2007;175:A510.
42. Kasperbauer S, Heifets L. **Daley CL**. Fluoroquinolone resistance in nontuberculous mycobacteria. *Am J Respir Crit Care Méd* 2007;175:S971.
43. Kasperbauer SH, Levin AR, Dexter M, Jarand J, Mitchell JD, Huitt G, Iseman M, Pomerantz M, **Daley CL**. Long term outcomes in patients with pulmonary *Mycobacterium avium* complex disease who undergo surgical resection. *Am J Respir Crit Care Med* 2008;177:A789.
44. Dexter ME, Levin AR, Kasperbauer SH, Schwiesow JN, Peloquin CA, **Daley CL**. Achieving target serum concentrations for patients with non-tuberculous mycobacterial infections. *Am J Respir Crit Care Med* 2008;177:A789
45. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, **Daley CL**. Risk factors for mortality in HIV-infected and non-infected patients with pulmonary tuberculosis. (IUATLD Global Lung Health Conference, Nov. 8-12, 2007, Cape Town, South Africa)
46. Pérez-Vélez, CM; Moreira-Restrepo, CA; Ferro-Ramos, BE; Wilson-Totten, SE; Dang-Ta, KC; **Daley, CL**; Heifets, LB Extensively drug-resistant tuberculosis in Colombia. (North American Region, IUATLD Conference, San Diego, CA Feb28-March 1, 2008)
47. Hernández-Ladino, NL; Pérez-Vélez, CM; Moreira-Restrepo, CA; González, LY; Cubides-Munevar AM; Casanova-Reynolds, AL; Wilches-Luna EC; Bolivar-Cuten, GA; **Daley, CL**. Operational research: the Valle-Colorado tuberculosis group. (North American Region, IUATLD Conference, San Diego, CA Feb28-March 1, 2008).
48. Nahid P, Metcalfe J, Gonzalez LC, Slymen DJ, Osmond DH, Kawamura LM, Hopewell PC, Daley CL. Tuberculosis contact investigation among drug users and homeless persons in San Francisco. *Am J Respir Crit Care Med* 2008;177:A581.

E. Manuscripts submitted

None

F. Manuscripts in preparation

1. Martinez A, Rudoy I, Ridzon R, Hopewell PC, Kawamura M, **Daley CL**. Rifampin mono-resistant tuberculosis in San Francisco.
2. **Daley CL**, Burgos M, Ponce de Leon A, Rudoy I, Small PM, Hopewell PC. Recurrent tuberculosis in San Francisco; relapse or reinfection?
3. Dexter ME, Wilson SE, Graham JJ, Levin A, Kasperbauer S, Heifets L, **Daley CL**. Fluoroquinolone susceptibility in Mycobacterium tuberculosis.
4. Kasperbauer S, Wilson SE, Graham JJ, Levin A, Dexter ME, Heifets L, **Daley CL**. Fluoroquinolone susceptibility in nontuberculous mycobacteria.
5. Perez-Velez CM, Moreira-Restrepo CA, Ferro-Ramos BE, Wilson-Totten SE, Dang-Ta KC, **Daley CL**, Heifets LB. Extensively drug resistant tuberculosis in Colombia.
6. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, **Daley CL**. Risk factors for mortality in HIV-infected and non-infected patients with pulmonary tuberculosis.

XII. Invited Lectures (selected)

1. "Tuberculosis", Advances in Infectious Diseases, San Francisco, May, 1991.
2. "Tuberculosis: Drug Interactions in HIV-infected Patients", California Tuberculosis Controllers Association, Stockton, CA, May, 1991.
3. "Outbreak of Tuberculosis in HIV-infected Patients". Grand Rounds, San Francisco General Hospital, January, 1992.
4. "Pleural and Pulmonary Tuberculosis", Department of Corrections Infectious Disease Symposium, Sacramento, CA, January 1992.
5. "Tuberculosis in the 1990's: New Challenges". Advances in Infectious Diseases, San Francisco, May 1992.
6. "Tuberculosis in the 1990's. Advances in Internal Medicine, San Francisco, May 1992.
7. "Nosocomial Pneumonia". Surgery Grand Rounds, UCSF, June 1992.
8. "Tuberculosis". Infectious Diseases Grand Rounds, UCSF, June 1992.
9. "Tuberculosis: New Challenges". Medical Grand Rounds, Kaiser Hospital, San Rafael, August 1992.
10. "Tuberculosis: Challenges for Human Medicine". Plenary session for World Veterinary Congress on Infectious Diseases, Univ. of California, Davis, September 1992.
11. "Tuberculosis: Current Research". Association of Infection Control Practitioners. San Bernardino, CA, October 1992.
12. "Tuberculosis and HIV infection: Treatment and Prevention". AIDS Program, Albany Medical Center, Albany, New York, December 1992.
13. "Multidrug-resistant Tuberculosis". San Jose Medical Center Grand Rounds. San Jose, CA, December 1992.
14. "Tuberculosis and HIV infection". Riverside County Health Department. January 1993.
15. "Multidrug-resistant Tuberculosis". Respiratory Infections for the Practicing Physician. Wichita, Kansas, March 1993.
16. "Tuberculosis in the 1990's" and "Molecular Epidemiology of Tuberculosis". Stringer Lecturer, American Lung Association, Michigan, April 1993.
17. "Tuberculosis and HIV infection". Sunrise Seminar, American Thoracic Society, San Francisco, May 1993.
18. "Tuberculosis—Why Prevention?". Keynote address at the California Tuberculosis Controllers Meeting, San Jose, CA, May 1993.

19. "Tuberculosis: Epidemiology and Treatment". Advances in Internal Medicine, San Francisco, June 1993.
20. "HIV and Tuberculosis". American Lung Association, Pebble Beach, CA, November 1993.
21. "Molecular Epidemiology of Tuberculosis". Meet the Professor Seminar, American Thoracic Society, Boston, May 1994.
22. "Tuberculosis: Causes and Cures for the Epidemic". Advances in Pulmonary and Critical Care Medicine, San Francisco, October 1994.
23. "Tuberculosis and HIV-Infection", Medical Grand Rounds, SFGH, 1995
24. "Tuberculosis and HIV-Infection", Plenary Session, American College of Veterinary Pathologists, Atlanta, November 16, 1995.
25. "Tuberculosis, New Challenges from an Old Disease", Advances in Pulmonary and Critical Care Medicine, UCSF, 1993-1997.
26. "Multidrug Resistant Tuberculosis", Epidemiology and Prevention of Infectious Diseases, UCSF, 1993-1996
27. "Update on Tuberculosis", American Assoc. of Academic Anesthesiologists, Boston, May, 1996.
28. "Current Issues in the Pathogenesis and Management of HIV-related Tuberculosis", Fort Miley VAH, San Francisco, Feb. 1997.
29. "Does Molecular Epidemiology Have a Message for Global TB Control?", International Union Against Tuberculosis and Lung Disease, Chicago, IL, March, 1997
30. "Molecular Epidemiology of Tuberculosis", Keynote address, 3rd European Workshop on Tuberculosis Control. Netherlands, June 27th, 1997.
31. "Tuberculosis and HIV". Plenary Session. California Tuberculosis Controllers Association. October 1997.
32. "Community Acquired Pneumonia" and "Tuberculosis", Peruvian Medical Association, Lima, Peru, 1997
33. "The Clinician/Laboratory Interface". National Laboratory Training Network Symposia. Miami, Tampa, Jacksonville, Orlando, Anchorage. 1998, 2001
34. "Molecular Epidemiology-Lessons for TB Control". International Congress of Pediatrics. Amsterdam, Netherlands, August 1998.
35. Prevention of Tuberculosis. Moving from TB Control to Elimination. Medicine Grand Rounds, UCSF, Feb 3, 2000
36. "HIV and TB", Tokyo University, Tokyo, Japan, Feb 2000
37. "Molecular Epidemiology of Tuberculosis in San Francisco, Public Health Research Institute, Osaka, Japan, Feb, 2000
38. "Molecular Epidemiology of Tuberculosis", American Thoracic Society, Toronto, May 2000
39. TB and HIV, Oaxaca, Mexico, 2000
40. "Global Epidemiology of Tuberculosis", Edmonton, Canada, March 21, 2001.
41. "Multidrug -Resistant Tuberculosis" - INER, Mexico City, March 19, 2002.
42. "Treatment of Tuberculosis" Rio de Janeiro, Brazil, March 26, 2002.
43. "Management of Drug Resistant Tuberculosis" Oaxtepec, Mx, Sept. 25, 2002.
44. " Delivering Treatment of Latent Infection to the Foreign-born" and " Identifying Latent TB Infection" World Conference on Lung Health, Montreal, Canada, Oct. 6-10, 2002.
45. "Lung Disease Update", American Lung Association of California, San Diego, CA Oct, 2002.
46. "Treatment of Tuberculosis, A US Perspective. HIV, STD Training Program. Phoenix, AZ 2002.
47. "International Implications of Tuberculosis. Unidos. Los Cruces, NM, Nov. 21, 2002.

48. "Treatment of multidrug resistance tuberculosis. An international approach. Oaxaca, Mexico, May 2-5, 2003.
49. "Global Tuberculosis Control", Emerging Infectious Diseases, June 20, 2003, San Francisco
50. "Target Practice" and "Global Tuberculosis Control", Northern Rockies Lung Association, Big Sky, Montana, March 14-16, 2003.
51. "Treatment of MDR-TB", Binational Tuberculosis Intensive, South Padre Island, TX, October 2003.
52. "New Tuberculosis Treatment Guidelines", Four Corner's Tuberculosis Controllers Association, Durango, California, October 28-29, 2003.
53. "Pulmonary Diseases". UCSF Internal Medicine Board Recertification Course. October, 2003.
54. "Latent Tuberculosis Infection". Public Health and Tuberculosis Conference, Anchorage, Alaska, February 19-21, 2004.
55. "Clinical and Radiographic Presentation of Tuberculosis". Annual Internal Medicine Society Conference, Jaurez, MX, March 2004.
56. "Multidrug-resistant tuberculosis". INER, Mexico City, March 24, 2004.
57. "The Challenges of Multidrug-resistant Tuberculosis". 79th Annual Meeting of the Japanese Tuberculosis Society, Nagoya, Japan, April 2004.
58. "Tuberculosis: Important Issues for the Respiratory Care Practitioner". Selected Topics in Intensive Respiratory Care. April 30, 2004. San Francisco.
59. "Atypical Mycobacteria" - Clinician's Center at ATS Meeting in Orlando, 2004.
60. "Treatment of Tuberculosis" – Utah Annual Tuberculosis Conference, 2004, 2005.
61. "New Tests for Latent Tuberculosis Infection". Oaxaca, MX, June, 2005.
62. "Advances in the Diagnosis and Treatment of Latent Tuberculosis Infection". 7th Seminar on Evidence-Based Infection Control. Tokyo, Japan, July, 2005
63. "Treatment of Tuberculosis Using the New CDC and WHO Hybrid Model", Tuberculosis Control in the Pacific Islands. Honolulu, Hawaii, Dec. 1-2, 2005.
64. "Regionalizing TB Control in Low Incidence Areas", Michigan Annual Tuberculosis Conference. Lansing, MI, Nov. 29, 2005.
65. "Advances in the Diagnosis and Treatment of Tuberculosis and Latent Infection", Spanish Pulmonary Society, Madrid Spain, March 1-3, 2006.
66. "Molecular Epidemiology of Tuberculosis". AG Holley Tuberculosis Hospital. Lantana, Florida, October 26, 2006.
67. "A New Global Plan to Control TB". Illinois Council on Tuberculosis. Peoria, IL, September 13, 2006.
68. "Tuberculosis in the Foreign-born". IDSA. Toronto, Canada, October 1, 2006.
69. "Management of Nontuberculous Mycobacterial Infections" IDSA. Toronto, Canada, October 14, 2006.
70. "Advances in the Diagnosis and Treatment of Latent TB Infection", Four Corners TB Conference, October 24, 2006.
71. "Advances in the Diagnosis and Treatment of Latent TB Infection", Keystone Conference, December 16, 2006.
72. "Epidemiology of Multidrug-resistant Tuberculosis" and "Management of Multidrug-resistant Tuberculosis". World TB Day, Dublin, Ireland, March 22, 2007.
73. "Management of Nontuberculous Mycobacterial Infections". Nymegen, Netherlands. September 2007.
74. "Gamma Interferon Release Assays; Is it time to replace the TST? Four Corners TB Conference. Durango, CO. October 2007

75. "Treatment and Clinical Outcomes of MDR/XDR-TB". IUATLD Global Lung Health Conference. Cape Town, South Africa, November 2007.
76. "Infection Control in the Era of MDR/XDR-TB: Duty to Care" International Nurses Council. Cape Town, South Africa, November 2007.
77. "Advances in the Diagnosis and Treatment of Tuberculosis" Taiwan, November 2007.

Television and Radio (not including brief radio or television interviews)

1. "Scientific Basis of Tuberculosis", one of four panel members in a three part satellite series taped at KQED and funded by the CDC, 1995.
2. "Tuberculosis and HIV", one hour radio interview on Taylor Satellite Talk network, 1996.
3. "Tuberculosis 2000", satellite broadcast from KQED, Jan 30, 1996.
4. "Whooping Cough", Channel 2, Denver, CO, 2004, 2005
5. "XDR-TB", World News Tonight, The Today Show, CNN, Good Morning America, etc.